FDA Approves First-in-Class Pancreatic Cancer Therapy

The U.S. Food and Drug Administration (FDA) has approved Rasonque (Daraxonrasib), a once-daily targeted therapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

How the New Drug Works

Rasonque is an oral RAS inhibitor designed to target multiple forms of the RAS protein, which plays an important role in driving cancer growth. RAS mutations are found in more than 90% of pancreatic ductal adenocarcinomas, the most common type of pancreatic cancer. The drug blocks active RAS signaling, potentially slowing the growth and spread of cancer cells.

According to the agency, Rasonque is a first-in-class targeted therapy for metastatic pancreatic cancer. Acting FDA Commissioner Kyle Diamantas, J.D., described the approval as a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer.

Results From Clinical Trials

The FDA’s approval was supported by a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. In the overall study population, patients who received Rasonque had a median overall survival of 13.2 months, compared with 6.7 months for those who received chemotherapy. The treatment reduced the risk of death by approximately 60%.

The study also found that Rasonque delayed cancer progression. Median progression-free survival was 7.2 months with Rasonque compared with 3.6 months with chemotherapy. Among the patients with RAS G12 mutations, which represented 91.8% of participants, median overall survival was 13.2 months with Rasonque compared with 6.6 months with chemotherapy.

Historically, patients with metastatic pancreatic cancer have had limited options once the disease progresses or after initial therapy fails. The results from the RASolute 302 trial showed that targeting the RAS pathway could provide a substantial survival benefit for people with previously treated metastatic pancreatic cancer. The findings were published in the New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology Annual Meeting.

This marks a shift in how doctors might approach treatment for this aggressive cancer. Rather than relying solely on standard chemotherapy, which attacks rapidly dividing cells indiscriminately, this new approach zeroes in on the genetic mutations that fuel the tumor’s growth. While the new drug does not cure the disease, it offers a new avenue to extend life for a population that has often been given few choices as the illness advances.

Side Effects and Safety Profile

As with any cancer treatment, Rasonque can cause side effects. The most common side effects reported with Rasonque include rash, diarrhea, stomatitis (inflammation of the mouth), nausea, fatigue, vomiting, abdominal pain, edema (swelling caused by fluid buildup), decreased appetite, and hemorrhage (bleeding).

In the phase 3 trial, 61.8% of patients receiving Rasonque experienced grade 3 or higher adverse events, compared with 69.6% of patients receiving chemotherapy. Treatment-related side effects led to discontinuation in 1.2% of patients receiving Rasonque and 11.2% of those receiving chemotherapy.

Patients should discuss potential side effects with their health care team before starting treatment and report new or worsening symptoms during therapy.

Approval Status and Designations

The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations and Priority Review for the application. The application was also reviewed through the Commissioner's National Priority Voucher pilot program, which is intended to accelerate review of treatments addressing national public health priorities.

The approval gives patients and their doctors another treatment option after previous therapy or for patients who are not candidates for multiagent chemotherapy. For patients with metastatic pancreatic adenocarcinoma, treatment decisions can depend on factors including previous therapies, overall health, tumor characteristics and the patient's goals and preferences. Patients should talk with their oncology team about whether Rasonque is appropriate for their individual situation.